Table 1 Characteristics of study patients and treatment
Demographic characteristics | |
|---|---|
Sex, n (%) (n = 116) | |
Male | 70 (60.3) |
Females | 46 (39.7) |
Clinical characteristics | |
Diagnosis, n (%) (n = 116) | |
Metastatic after relapse/progression | 25 (21.6) |
De novo metastatic | 91 (78.4) |
% Weight loss in the last 3 mo (median, Q1, Q3) (n = 74) | 9.2 (4.5, 14.1) |
Weight loss > 10%, n (%) | 33 (44.6) |
CA 19.9 UI/mL (median, Q1, Q3) (n = 90) | 725.7 (83.0, 7323.0) |
Comorbidities, n (%) (n = 116) | |
Hypertension | 48 (41.4) |
Diabetes | 35 (30.2) |
Performance Status | |
ECOG Performance Status, n (%) (n = 103) | |
0–1 | 84 (81.6) |
2 | 19 (18.4) |
Karnofsky Index, n (%) (n = 115) | |
90–100 | 60 (52.2) |
70–80 | 55 (47.8) |
Treatment characteristics and outcome | |
Treatment, n (%) (n = 113) | |
Gemcitabine + nab-paclitaxel | 73 (64.6) |
Gemcitabine monotherapy | 21 (18.6) |
FOLFIRINOX or mFOLFIRINOX | 14 (12.4) |
Other combinations | 5 (4.4) |
Treatment schedule, n (%) (n = 101) | |
Patients with any change in the dose or schedule | 57 (56.4) |
Patients with any delay in the treatment | 59 (58.4) |
Reasons for treatment discontinuation, n (%) (n = 111)a | |
Progression | 60 (54.1) |
Toxicity | 15 (13.5) |
Clinical deterioration | 15 (13.5) |
Lost to follow-up | 1 (0.9) |
Voluntary withdrawal of the study | 1 (0.9) |
Death | 3 (2.7) |
Other reasons | 19 (17.1) |
Best response obtained in the first-line treatment, n (%) (n = 87) | |
Complete response | 3 (3.4) |
Partial response | 24 (27.6) |
Stable disease | 32 (36.8) |
Progression | 28 (32.2) |